Myeloproliferative Neoplasms Therapeutics
1. Rytelo patent expiration
Treatment: Treatment of patients with myelodysplastic syndromes (mds) with transfusion-dependent anemia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7494982 | GERON | Modified oligonucleotides for telomerase inhibition |
Dec, 2025
(12 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12442000 | GERON | NA |
Mar, 2033
(7 years from now) | |
| US9388416 | GERON | Modified oligonucleotides for telomerase inhibition |
Sep, 2026
(7 months from now) | |
| US9388415 | GERON | Modified oligonucleotides for telomerase inhibition |
Sep, 2026
(7 months from now) | |
| US9375485 | GERON | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
Mar, 2033
(7 years from now) | |
| US12171778 | GERON | Methods of treating myelodysplastic syndrome |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-482) | Jun 06, 2031 |
Drugs and Companies using IMETELSTAT SODIUM ingredient
Market Authorisation Date: 06 June, 2024
Dosage: POWDER
More Information on Dosage
RYTELO family patents
